MetrioPharm AG was founded in 2007 by an experienced team of medical professionals and entrepreneurs. Their goal was the further development of a class of small molecule compounds. These had shown promising anti-inflammatory effects in experiments.
The first step in pharmaceutical development was the characterization of stable and bioavailable dosage forms. The result of this search were several pharmaceutically effective variants of the molecule family: the MP1000 platform, which encompasses the lead compound MP1032.
In the following years, this compound was tested in various preclinical trials. MP1032 showed efficacy in a wide range of disease models. MetrioPharm AG focused its research on the treatment of immune-induced inflammatory diseases ("IMIDs"). These include rheumatoid arthritis, psoriasis and multiple sclerosis. Today, the focus is on chronic inflammatory diseases and especially on age-related inflammation (inflamm-aging).
In 2015, the company reached a pivotal milestone: the start of clinical development of its lead compound. MP1032 demonstrated an exceptionally good safety profile in humans in the Phase I study.
This first clinical trial was immediately followed by an exploratory Phase IIa study in psoriasis. This study was successfully completed in 2017.
In 2018, MetrioPharm AG initiated a Phase II dose-finding study in psoriasis. This was successfully completed in 2019: clinical efficacy was demonstrated for MP1032 and the excellent safety profile was confirmed.
In parallel to the clinical development of MP1032, the scientific team worked on clarifying the mechanism of action. MetrioPharm AG was able to demonstrate that MP1032 modulates a fundamental trigger of chronic inflammation and diseases of aging: the drug is the first self-regulating radical-scavenger to target pathological oxygen radicals.